Kubota S, Furuta R A, Hatanaka M, Pomerantz R J
Dorrance H. Hamilton Laboratories, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Biochem Biophys Res Commun. 1998 Feb 4;243(1):79-85. doi: 10.1006/bbrc.1997.8065.
The 5'-RU5 portion of human T-lymphocyte virus type I (HTLV-I) long terminal repeat (LTR) had been reported to contain cis-acting elements for the controlled viral gene expression by the rex gene product. In this study, the human immunodeficiency virus type I (HIV-1) Rev protein was found to enhance gene expression, acting through the 5'-RU5 portion of HTLV-I, while the Rex-responsive element (RxRE)-mediated activation by Rev was reconfirmed to be negative. This positive action of HIV-1 Rev on HTLV-I gene expression seemed to be distinct from the widely accepted Rex or Rev function to facilitate the nuclear export of RxRE-containing unspliced viral mRNAs, since a trans-dominant, nuclear export-deficient mutant (RevM10) still retained the RU5-mediated effector function. Analyses of the functional aspects of Tat/Rev fusion proteins on the HTLV-I RU5 suggested a specific interaction of Rev and RU5, but lacked evidence for the binding of Rev to the RU5 at the RNA level. These results suggest an answer to the controversy regarding a Rex-like function occasionally observed with HIV-1 Rev and its related proteins. It may also be suggested that particular care should be taken when such a trans-dominant Rev mutant is considered to be used as a genetic therapy against HIV-I infection, in individuals infected with both HIV-I and HTLV-1.
据报道,人类I型T淋巴细胞病毒(HTLV-I)长末端重复序列(LTR)的5'-RU5部分含有顺式作用元件,可通过rex基因产物控制病毒基因表达。在本研究中,发现人类免疫缺陷病毒I型(HIV-1)Rev蛋白通过HTLV-I的5'-RU5部分发挥作用,增强基因表达,而Rev对Rex反应元件(RxRE)介导的激活再次被证实为阴性。HIV-1 Rev对HTLV-I基因表达的这种正向作用似乎不同于广泛接受的Rex或Rev促进含RxRE的未剪接病毒mRNA核输出的功能,因为一种反式显性、核输出缺陷型突变体(RevM10)仍保留RU5介导的效应功能。对Tat/Rev融合蛋白在HTLV-I RU5上功能方面的分析表明Rev与RU5存在特异性相互作用,但缺乏Rev在RNA水平上与RU5结合的证据。这些结果为关于HIV-1 Rev及其相关蛋白偶尔观察到的类Rex功能的争议提供了答案。这也可能表明,在同时感染HIV-1和HTLV-1的个体中,当考虑将这种反式显性Rev突变体用作抗HIV-1感染的基因治疗时,应格外小心。